Literature DB >> 22551518

Identification and characterization of triamcinolone acetonide, a microglial-activation inhibitor.

Jinpyo Hong1, Bo-Kyong Kim, Hyoungsub Lim, Soojin Lee, Sung Joong Lee.   

Abstract

Recent studies show that necrotic neuronal cells (NNC) activate microglia, thereby leading to neuronal cell death. This suggests that chemicals that inhibit microglia activation may be used as neuroprotective drugs. In this context, we screened a chemical library for inhibitors of microglia activation. Using a screening system based on a nitrite assay, we isolated two chemicals that inhibit nitric oxide (NO) release from activated microglia: triamcinolone acetonide (TA) and amcinonide. The half-maximal inhibitory concentrations (IC50) of TA and amcinonide for NO release inhibition were 1.78 nM and 3.38 nM, respectively. These chemicals also inhibited NNC-induced expression of the proinflammatory genes iNOS, TNF-α, and IL-1β in glial cells. A study based on a luciferase assay revealed that TA attenuated NNC-induced microglia activation by blocking the NF-κB signaling pathway. In addition, TA protected cortical neurons in coculture with microglia from LPS/IFN-γ-induced neuronal cell death. In conclusion, TA may inhibit microglia activation and may protect neuronal cells from death induced by microglial activation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22551518     DOI: 10.3109/08923973.2012.671332

Source DB:  PubMed          Journal:  Immunopharmacol Immunotoxicol        ISSN: 0892-3973            Impact factor:   2.730


  5 in total

1.  Intracellular delivery of dendrimer triamcinolone acetonide conjugates into microglial and human retinal pigment epithelial cells.

Authors:  Siva P Kambhampati; Manoj K Mishra; Panagiotis Mastorakos; Yumin Oh; Gerard A Lutty; Rangaramanujam M Kannan
Journal:  Eur J Pharm Biopharm       Date:  2015-02-19       Impact factor: 5.571

Review 2.  Inhibition of microglia activation as a phenotypic assay in early drug discovery.

Authors:  Mariana Figuera-Losada; Camilo Rojas; Barbara S Slusher
Journal:  J Biomol Screen       Date:  2013-08-14

3.  Dendrimer-Triamcinolone Acetonide Reduces Neuroinflammation, Pathological Angiogenesis, and Neuroretinal Dysfunction in Ischemic Retinopathy.

Authors:  Hongkwan Cho; Siva P Kambhampati; Michael J Lai; Lingli Zhou; Grace Lee; Yangyiran Xie; Qiaoyan Hui; Rangaramanujam M Kannan; Elia J Duh
Journal:  Adv Ther (Weinh)       Date:  2020-11-09

4.  Polyamidoamine dendrimer-conjugated triamcinolone acetonide attenuates nerve injury-induced spinal cord microglia activation and mechanical allodynia.

Authors:  Hwisung Kim; Boomin Choi; Hyoungsub Lim; Hyunjung Min; Jae Hoon Oh; Sunghyun Choi; Joung Goo Cho; Jong-Sang Park; Sung Joong Lee
Journal:  Mol Pain       Date:  2017-01       Impact factor: 3.395

5.  A Novel Mathematical Model of Glaucoma Pathogenesis.

Authors:  Muneeb A Faiq; Talvir Sidhu; Rayees A Sofi; Himanshu N Singh; Rizwana Qadri; Rima Dada; Shibal Bhartiya; Meghal Gagrani; Tanuj Dada
Journal:  J Curr Glaucoma Pract       Date:  2019 Jan-Apr
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.